Shuoxing Biopharma's Innovative Nanobody Multispecific SM3321 Receives FDA IND Approval for Clinical Development in Acute Myeloid Leukemia

Recently, Beijing StarMab BioMed Technology Ltd. (referred to as StarMab BioMed) announced that its self-developed nanomulti-antibody SM3321 has been approved by the U.S. FDA for clinical research. SM3321 is the world's first nanomulti-antibody drug approved by the FDA for the treatment of acute myeloid leukemia (AML).